黑料网

Stergios Moschos, MD, has a research focus on identifying molecules that are important for melanoma development and progression, identifying mechanisms of action of FDA-approved and investigational agents in melanoma.

For example, he identified that Ubc9, the single SUMO E2 conjugating enzyme is highly expressed in melanoma-infiltrated lymph nodes and that targeting Ubc9 in melanoma cell lines enhances the cytotoxic effect of chemotherapeutic agents. Furthermore, he studied the mechanism of action of high-dose interferon as part of a neoadjuvant trial in patients with stage III melanoma.

David Ollila, MD, is a general surgical oncologist with broad training in all aspects of surgical oncology. His special areas of interest are in melanoma, breast cancer, and the surgical management of endocrine disorders, with a focus on providing a translational step for basic scientists between the laboratory and the clinic. During his training at John Wayne Cancer Institute, Ollila became very familiar with the polyvalent melanoma vaccines being studied there. At 黑料网, he has initiated two vaccine clinical trials that will lead to further immunotherapy research and clinical applications in this area. Ollila is planning collaborative work on melanoma sentinel nodes in an epidemiology study being run by the 黑料网 School of Public Health.

Ollila鈥檚 breast cancer research interests include work derived from his expertise in sentinel node biopsy, a technique for identifying the lymph node most likely to contain cancer metastasis. He was one of the first to examine the use of sentinel lymph node biopsy as a method to improve the ability to determine tumor extent and minimize surgery in women undergoing neoadjuvant, or preoperative, chemotherapy. He has also developed a method using a new technique for identifying cancer, positron emission tomography (PET) to help guide surgery after chemotherapy. This method is being tested in an ongoing clinical trial.